These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 11991997

  • 21. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X, Kandasamy K, Srivastava RK.
    Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723
    [Abstract] [Full Text] [Related]

  • 22. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.
    Apoptosis; 2006 Jul 01; 11(7):1175-93. PubMed ID: 16699949
    [Abstract] [Full Text] [Related]

  • 23. IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression.
    Tanaka F, Kawakami A, Tamai M, Nakamura H, Iwanaga N, Izumi Y, Arima K, Aratake K, Huang M, Kamachi M, Ida H, Origuchi T, Eguchi K.
    Int J Mol Med; 2005 May 01; 15(5):833-9. PubMed ID: 15806306
    [Abstract] [Full Text] [Related]

  • 24. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
    Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ.
    J Invest Dermatol; 2001 Oct 01; 117(4):898-907. PubMed ID: 11676830
    [Abstract] [Full Text] [Related]

  • 25. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T.
    Hum Pathol; 2005 Oct 01; 36(10):1066-73. PubMed ID: 16226105
    [Abstract] [Full Text] [Related]

  • 26. Involvement of TRAIL and its receptors in viral hepatitis.
    Mundt B, Kühnel F, Zender L, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S.
    FASEB J; 2003 Jan 01; 17(1):94-6. PubMed ID: 12475902
    [Abstract] [Full Text] [Related]

  • 27. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J.
    J Invest Dermatol; 2005 Nov 01; 125(5):1010-9. PubMed ID: 16297203
    [Abstract] [Full Text] [Related]

  • 28. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
    Kajiwara K, Saito A, Ogata S, Tanihara M.
    Biochim Biophys Acta; 2004 Jun 01; 1699(1-2):131-7. PubMed ID: 15158720
    [Abstract] [Full Text] [Related]

  • 29. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice.
    Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T.
    Hepatology; 2004 May 01; 39(5):1321-31. PubMed ID: 15122761
    [Abstract] [Full Text] [Related]

  • 30. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.
    Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS.
    Cancer Res; 1999 Jun 15; 59(12):2770-5. PubMed ID: 10383128
    [Abstract] [Full Text] [Related]

  • 31. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
    Higuchi H, Bronk SF, Taniai M, Canbay A, Gores GJ.
    J Pharmacol Exp Ther; 2002 Nov 15; 303(2):461-7. PubMed ID: 12388624
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.
    Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H, Chen-Kiang S.
    J Immunol; 2002 Nov 15; 169(10):5505-13. PubMed ID: 12421926
    [Abstract] [Full Text] [Related]

  • 34. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ.
    Cancer Res; 2000 Feb 15; 60(4):847-53. PubMed ID: 10706092
    [Abstract] [Full Text] [Related]

  • 35. [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells].
    Ma YF, Zhang J, Zhao YP, Yang DL, Chen YH.
    Zhonghua Zhong Liu Za Zhi; 2004 Sep 15; 26(9):528-30. PubMed ID: 15555281
    [Abstract] [Full Text] [Related]

  • 36. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
    Gong B, Almasan A.
    Cancer Res; 2000 Oct 15; 60(20):5754-60. PubMed ID: 11059770
    [Abstract] [Full Text] [Related]

  • 37. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines.
    Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS.
    Int J Oncol; 2001 Feb 15; 18(2):241-7. PubMed ID: 11172588
    [Abstract] [Full Text] [Related]

  • 38. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 39. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses.
    Droin NM, Pinkoski MJ, Dejardin E, Green DR.
    Mol Cell Biol; 2003 Nov 15; 23(21):7638-47. PubMed ID: 14560009
    [Abstract] [Full Text] [Related]

  • 40. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 15; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.